Form 4: Solid Biosciences Director Nagendran Sukumar Granted Stock Options

Director Nagendran Sukumar of Solid Biosciences Inc. was granted stock options on June 11, 2024.

Summary

• Sukumar Nagendran, a director of Solid Biosciences Inc., received stock options on June 11, 2024.
• The options grant gives Nagendran the right to buy 34,400 shares of Solid Biosciences' common stock at an exercise price of $7.51 per share.
• The options vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date.
• The options will also vest automatically as to 100% of the unvested portion upon specified change in control events.
• The options expire on June 11, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine grant of stock options to a director, which is a common practice.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The size of the grant (34,400 shares) and the vesting schedule (one year or change in control) appear to be within typical ranges for director compensation at similar-sized biotech companies.
• Comparable companies such as Sarepta Therapeutics or BioMarin Pharmaceutical also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grant relative to the company's total outstanding shares.

Key Dates